John Lee
Adult Medicine · Murfreesboro, TNNPI 1134502016
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 228 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$630
- Lilly USA, LLC$458
- AstraZeneca$373
- Pfizer$363
- GSK$336
- Amgen$288
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,56098%
- Education$622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $630 |
| Lilly USA, LLC | 33 | $458 |
| AstraZeneca(2 entities) | 19 | $373 |
| Pfizer | 22 | $363 |
| GSK | 17 | $336 |
| Amgen | 18 | $288 |
| AbbVie(2 entities) | 14 | $253 |
| Boehringer Ingelheim | 9 | $175 |
| Merck | 7 | $95 |
| Johnson & Johnson | 6 | $94 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Dynavax Technologies Corporation | 5 | $67 |
| Astellas Pharma US Inc | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $61 |
| Novartis | 3 | $45 |
| Adlon Therapeutics L.p. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,622 in reported general payments places this provider in the 70th percentile of 22 adult medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $53,262 |
| EliquisApixaban | 20 | $19,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $8,934 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 13 | $4,138 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 15 | $3,268 |
| Rosuvastatin Calcium | 157 | $2,849 |
| Atorvastatin Calcium | 171 | $2,031 |
| Clonidine | 16 | $1,756 |
| Solifenacin Succinate | 11 | $1,749 |
| Verapamil SrVerapamil Hcl | 11 | $1,543 |
| Losartan Potassium | 103 | $1,146 |
| Metformin Hcl ErMetformin Hcl | 98 | $1,078 |
| Metoprolol Succinate | 61 | $1,033 |
| Fluticasone Propionate | 31 | $981 |
| Lisinopril | 112 | $909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $630 | $53,26231 claims |
| PfizerEliquis | $363 | $19,11220 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $336 | $16,33943 claims |
| AbbVieSynthroid | $253 | $69111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 22 adult medicine providers in Tennessee.
Other adult medicine in Murfreesboro
- Michael KelloggGallatin$19K
- Paul BoeremaCleveland$11K
- Dennis ThompsonCleveland$10K
- William HaysCleveland$10K
- Cynthia ShafferOoltewah$5K
- Allan ChastainCleveland$4K
- Bojidar DolaptchievNewport$2K
- John SherrillBristol$1K
- Jung ParkDunlap$889
- Jill WallnerCrossville$686
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.